Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Am J Respir Crit Care Med ; 186(11): 1117-24, 2012 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-23024024

RESUMO

RATIONALE: Chronic obstructive pulmonary disease (COPD) exacerbations are associated with virus (mostly rhinovirus) and bacterial infections, but it is not known whether rhinovirus infections precipitate secondary bacterial infections. OBJECTIVES: To investigate relationships between rhinovirus infection and bacterial infection and the role of antimicrobial peptides in COPD exacerbations. METHODS: We infected subjects with moderate COPD and smokers and nonsmokers with normal lung function with rhinovirus. Induced sputum was collected before and repeatedly after rhinovirus infection and virus and bacterial loads measured with quantitative polymerase chain reaction and culture. The antimicrobial peptides secretory leukoprotease inhibitor (SLPI), elafin, pentraxin, LL-37, α-defensins and ß-defensin-2, and the protease neutrophil elastase were measured in sputum supernatants. MEASUREMENTS AND MAIN RESULTS: After rhinovirus infection, secondary bacterial infection was detected in 60% of subjects with COPD, 9.5% of smokers, and 10% of nonsmokers (P < 0.001). Sputum virus load peaked on Days 5-9 and bacterial load on Day 15. Sputum neutrophil elastase was significantly increased and SLPI and elafin significantly reduced after rhinovirus infection exclusively in subjects with COPD with secondary bacterial infections, and SLPI and elafin levels correlated inversely with bacterial load. CONCLUSIONS: Rhinovirus infections are frequently followed by secondary bacterial infections in COPD and cleavage of the antimicrobial peptides SLPI and elafin by virus-induced neutrophil elastase may precipitate these secondary bacterial infections. Therapy targeting neutrophil elastase or enhancing innate immunity may be useful novel therapies for prevention of secondary bacterial infections in virus-induced COPD exacerbations.


Assuntos
Peptídeos Catiônicos Antimicrobianos/metabolismo , Coinfecção/etiologia , Infecções por Picornaviridae/complicações , Doença Pulmonar Obstrutiva Crônica/microbiologia , Doença Pulmonar Obstrutiva Crônica/virologia , Rhinovirus , Adulto , Idoso , Análise de Variância , Infecções Bacterianas/etiologia , Infecções Bacterianas/fisiopatologia , Proteína C-Reativa/análise , Proteína C-Reativa/metabolismo , Estudos de Coortes , Coinfecção/fisiopatologia , Progressão da Doença , Elafina/análise , Elafina/metabolismo , Feminino , Humanos , Mediadores da Inflamação/análise , Masculino , Pessoa de Meia-Idade , Infecções por Picornaviridae/fisiopatologia , Reação em Cadeia da Polimerase/métodos , Prognóstico , Estudos Prospectivos , Doença Pulmonar Obstrutiva Crônica/complicações , Medição de Risco , Inibidor Secretado de Peptidases Leucocitárias/análise , Inibidor Secretado de Peptidases Leucocitárias/metabolismo , Componente Amiloide P Sérico/análise , Componente Amiloide P Sérico/metabolismo , Índice de Gravidade de Doença , Fumar , Escarro/citologia , Estatísticas não Paramétricas
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa